证券日报网讯 2月27日，翔宇医疗发布2025年度业绩快报公告称，公司2025年度实现营业总收入 76774.74万元，同比增长3.26%；实现归属于母公司所有者的净利润7869.90万元，同比减少23.55%。 （文章来源：证券日报） ...

报告期内，公司坚持科技创新，提升管理运营效率，营业收入较上年同期略有增长。同时公司持续引进 高端康复技术人才，研发人员薪酬及相关费用有所增加，加以公司建设项目陆续投入使用、折旧摊销较 上年有所增加，致使公司归属于母公司所有者的净利润和归属于母公司所有者的扣除非经常性损益的净 利润下降。 格隆汇2月27日丨翔宇医疗(688626.SH)公布2025年度业绩快报，本报告期，公司实现营业总收入 76,774.74万元，同比增长3.26%；实现归属于母公司所有者的净利润7,869.90万元，同比减少23.55%； 实现归属于母公司所有者的扣除非经常性损益的净利润5,895.43万元，同比减少34.48%。 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2026-003 河南翔宇医疗设备股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以河南翔宇医疗设备股份有限公司（以下简称"公司"）2025年年 度报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 76,774.74 | 74,353.13 | 3.26 | | 营业利润 | 7,706.91 | 10,851.34 | -28.98 | | 利润总额 | 7,479.22 | 10,723.52 | -30.25 | | 归属于母公司所有者的净利润 | 7,869.90 | 10,294.36 | -23.55 | | 归属于母公司所有者的扣除非 经常性损益的净利润 | 5, ...

翔宇医疗公告称，2025年度公司实现营业总收入76774.74万元，同比增长3.26%；归属于母公司所有者 的净利润7869.90万元，同比减少23.55%；扣除非经常性损益的净利润5895.43万元，同比减少34.48%。 报告期末，公司总资产326863.19万元，同比增长11.64%；归属于母公司的所有者权益207010.39万元， 同比增加1.54%。业绩变动主要因研发人员薪酬等费用及折旧摊销增加。具体数据以2025年年度报告为 准。 ...

"在'政策+资本+技术'等多重因素催化下，国内脑机接口商业化进程加速推进，未来将逐步从'神经康 复'向'认知提升'再向'脑机融合'时代迈进。"中信证券分析称。 ● 本报记者 李梦扬 Wind数据显示，截至2月26日记者发稿时，今年以来共有80家医药生物行业上市公司接受机构调研。值 得关注的是，翔宇医疗、爱朋医疗、美好医疗等脑机接口概念股吸引多家机构调研，脑机接口产品研发 进展、商业化情况、未来发展规划等成为机构关注的焦点。与此同时，创新药出海热度不减，多家药企 亦获机构关注。 业内人士表示，AI大科技浪潮下，医药行业有望释放新的成长逻辑，继续看好以创新为主的医药科技 主线，重点关注脑机接口、AI医疗、创新药出海等。 脑机接口概念股备受青睐 Wind数据显示，截至2月26日记者发稿时，今年以来接受机构调研频次前十的医药生物公司中，翔宇医 疗获机构关注度最高，累计接受机构调研208家次；爱朋医疗、美好医疗分居第二、第三位，接受机构 调研频次分别为177家次、125家次；博拓生物、欧林生物、泰恩康等紧随其后，接受机构调研均在90家 次以上。 值得一提的是，机构频频调研脑机接口概念股。"脑机接口是'十五五'期间未来产 ...

经济观察网翔宇医疗(688626)2026年有多项已公告或计划中的事件值得关注。 产品研发进展 公司计划在2026年推出数十款脑机接口等新产品，进一步丰富康复医疗设备矩阵，并将脑机接口技术升 级至多模态、多范式体系。 公司业绩目标 脑机接口相关产品预计在2026年对业绩提升起到较大促进作用，目前已在150余家大型医院进行临床使 用与课题合作。 公司项目推进 高管变动 公司控股股东一致行动人安阳启旭贸易咨询服务中心(有限合伙)计划于2026年2月4日至5月3日期间减持 不超过公司总股本3%的股份。 公司目标在2026年将产品覆盖扩展至超1000家三甲医院，目前产品已进入500多家三甲医院。 业务进展情况 公司正积极推进投资并购事宜，以整合行业资源，投融资工作有序进行中。此外，公司牵头申报的河南 省脑机接口康复设备技术创新中心已于2026年1月获批成为省级平台，可能持续推动技术研发。 以上内容基于公开资料整理，不构成投资建议。 ...

Group 1 - The core viewpoint of the article highlights the increasing investment and research activity in the brain-computer interface (BCI) industry in China, with a focus on key companies and patent trends [1][4][5] Group 2 - The research and development investment in the BCI industry by listed companies in China is steadily increasing from 2020 to 2024, indicating a strengthening of R&D efforts [1] - The number of patent applications in China's BCI industry showed a steady growth trend, peaking at 258 applications in 2021, followed by a decrease to 209 applications in 2024 [4] - Tianjin University is identified as the leading patent applicant in the BCI sector, with a total of 126 related patents, followed by South China University of Technology and Xi'an Jiaotong University with 80 and 78 patents respectively [5][7] - The most popular technology patents in the BCI industry are in the category of electrical digital data processing (G06F), with a total of 1,013 patents, followed by diagnostic and surgical technologies (A61B) with 712 patents, and specific computing models (G06N) with 313 patents [8]

Core Insights - Insurance capital management is increasingly focused on deep research of individual stocks and industries, with significant interest in A-share listed companies as indicated by over 300 companies being researched since the beginning of 2026 [1][2] Group 1: Research Trends - A total of 96 insurance companies and 32 insurance asset management companies have participated in the research of A-share listed companies since the beginning of 2026 [2] - Key players such as Taiping Pension, Changjiang Pension, and China Life Pension have conducted over 30 research sessions each within a month [2] - Regional banks and sectors like electronic components, semiconductor materials, and devices are receiving heightened attention from insurance capital [2] Group 2: Investment Strategies - Insurance capital views company research as a crucial part of investment strategy, often focusing on high-quality stocks with long-term growth potential [3] - The demand for high dividend stocks is driven by the need for stable cash flow in a low-interest-rate environment, with banks being a primary focus for insurance capital [4] - Insurance capital is increasingly adopting a dividend strategy, favoring high dividend stocks to stabilize returns amid pressure on fixed-income yields [4] Group 3: Focus on New Productive Forces - Insurance capital is aligning with long-term investments in new productive forces, particularly in technology innovation and emerging strategic industries [5] - There is a focus on investing in sectors with real technological barriers and clear business models that can deliver performance [5] Group 4: Investment Paths - For mature technology leaders, insurance capital is likely to invest directly for excess returns, while for emerging tech sectors, indirect investments through ETFs or industry funds are preferred to manage risks [6] - The insurance capital sector is particularly interested in AI-driven technology and high-end manufacturing, with a strategy to invest in companies with clear business models and strong competitive advantages [6]

Group 1 - The core viewpoint of the articles highlights the increasing interest of insurance capital in specific sectors and companies, particularly in regional banks and new productivity sectors, as indicated by their extensive research activities [1][2][3] - Since the beginning of 2026, over 300 A-share listed companies have been researched by insurance companies and asset management firms, with significant participation from 96 insurance companies and 32 asset management companies [2] - Key areas of focus for insurance capital include regional banks such as Shanghai Bank and Nanjing Bank, as well as sectors like electronic components, semiconductor materials, and devices [2][3] Group 2 - Insurance capital is increasingly favoring high-dividend stocks as a stable source of cash flow, particularly in a low-interest-rate environment, which drives the demand for equity assets [4] - The strategy of investing in high-dividend stocks is seen as a way to enhance returns and stabilize portfolios, with a focus on long-term holdings and dividend yields [4][5] - The shift towards high-dividend stocks is also a response to new accounting standards that increase profit statement volatility, making these investments more attractive [4] Group 3 - Insurance capital is aligning with the new productivity sector, which relies on technological innovation and strategic emerging industries, requiring long-term and stable capital support [5][6] - Investments are being directed towards technology leaders with clear business models and performance track records, while emerging tech sectors may be approached through industry-themed ETFs or funds to mitigate risks [6] - The focus on AI-driven technology and high-end manufacturing is expected to be central to future technological revolutions, with a commitment to direct investments in companies with strong competitive advantages [6]

今年以来，机构调研热度持续攀升。Wind资讯数据显示，1月1日至2月5日，已有超700家上市公司接受 机构调研。 头部企业的"出海"表现也成为机构调研的焦点之一。大金重工是国内风电塔筒行业首家上市企业，公司 相关负责人透露，公司在德国海风基础领域市占率很高，项目交付业绩出色，并且在德国库克斯哈芬港 口已锁定码头，未来用于开展本地化服务；公司在波兰市场已完成布局，拥有员工储备，且具备本地化 安装和检验的项目经验。 "机构对计算机、医药生物及电子板块的密集调研，本质上是对新兴科技从概念窗口期迈向业绩兑现期 的深度摸底。以脑机接口和具身智能为代表的交叉学科技术，正加速商业化闭环进程。"深度科技研究 院院长张孝荣对《证券日报》记者表示。 排排网财富公募产品运营曾方芳对《证券日报》记者表示："2026年机构调研更加聚焦企业技术研发进 展、订单签订及落地情况，重点围绕AI产业链、先进制造等高景气赛道展开，具备硬科技属性和可持 续盈利模式的企业正成为资金布局的重点。" （文章来源：证券日报） 从行业分布来看，计算机、机械设备、医药生物和电子板块成为机构关注的重点。大金重工股份有限公 司（以下简称"大金重工"）、北京海天瑞声 ...